Xingqi Eye Pharmaceutical (300573.SZ): First subject enrolled in Phase I clinical trial of SQ-24071 eye drops
Zhitong Finance APP news, Xingqi Eye Medicine (300573.SZ) announced that the SQ-24071 eye drops developed by the company recently completed the first patient enrollment in the "multicenter, randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of SQ-24071 eye drops in children and adolescent participants with myopia," officially entering Phase I clinical trials.
Latest

